Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Lack Of Information Fuels Cancer Screening Fears According To Review Covering Nearly 6,000 Women
Fear plays a major role in whether women decide to go for cancer screening or not, but healthcare providers underestimate how much women need to know and wrongly assume that they will ask for information if they want it.
generic viagra online
Malpractice Suits, Other Factors Contribute To Rise In Caesarean Births, Experts Say
Many doctors believe that the increase in caesarean section births in the U.S. over the last decade has been fueled by three main factors -- fear of malpractice lawsuits, a decrease in vaginal births after c-sections and rising rates of obesity -- the St. Petersburg Times reports. According to the Times, 31.8% of U.S. births were c-sections in 2007, compared with 21% a decade earlier, making c-sections the most commonly performed procedure in the nation"s hospitals.A few decades ago, c-section births were relatively rare, representing only 4% of U.S. births in 1965. According to the Times, c-section rates began to increase when it was believed that many cerebral palsy cases were the result of infants being deprived of oxygen during traumatic vaginal deliveries, which led to malpractice suits against doctors. At the same time, advancements in neonatal care and electronic fetal monitoring in recent decades have helped make the procedure safer and therefore more common. Robert Yelverton, a physician and board member of the Florida Obstetric and Gynecologic Society, said that doctors "tend to opt for the method of childbirth most likely to withstand a legal challenge." Whereas doctors in the past were more likely to use techniques such as vacuum extraction or manually turning an infant during a difficult birth, doctors today automatically opt for a c-section, according to Yelverton. According to the Times, one study found that 76% of U.S. obstetricians reported at least one litigation event, with an average award of $2.3 million for negligence in childbirth.An increase in obesity and a decline in VBACs also have driven the rise in c-section births, the Times reports. VBACs have declined from nearly 30% in the 1990s to 7.9% in 2005, which some doctors say is a result of fear of litigation because of the chance for rare but serious complications during birth. Similarly, obesity puts women at an increased risk for gestational diabetes, delivering prematurely or having larger infants, which can make birth more risky, the Times reports. More than one-third of U.S. women of childbearing age are overweight or obese (Martin, St. Petersburg Times, 6/17).
News of the day
Change4Life Corner Shops To Open Across The Country, UK
Corner shops nationwide will get help from Change4Life to sell fruit and veg - this will mean more people will get their 5 a day and shops will see an increase in profits, Secretary of State for Health Andy Burnham said today.
Nutrition

IFX Anti-TNF Therapy Associated With Clinical Benefit Over 5 Years In Patients With Active AS

After five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% of patients with ankylosing spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ASAS partial remission. Moreover, at five years, 78.4% of AS patients had no arthritis and 84.9% had no enthesitis (inflammation at the junction between tendon and bone). Over this period, patients continued to show a sustained high response rate, low disease activity, good functional state and low creactive protein (CRP, a marker for inflammation) levels, according to the results of a new openlabel follow-up study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. AS is the most frequent chronic inflammatory rheumatic disease that characteristically affects the axial skeleton, entheses (sites where ligaments and tendons attach to bone) and peripheral joints. In consequence, new bone formation may result - eventually leading to ankylosis (fusion of vertebral bodies). Typical symptoms of AS include inflammatory back pain and spinal stiffness. Dr Frank Heldmann, Centre of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, the coordinator of the study, said: "Until now, our knowledge on the long-term efficacy of anti-TNF therapy in AS has remained rather limited, but the EASIC study group has significantly contributed to furthering this. Since anti-TNF agents are a relatively new treatment option for patients with AS, and can be required for long periods of time, there is strong need to know about their long-term efficacy and safety. The data show that infliximab therapy was associated with sustained efficacy and favourable attrition rates (less than 10% per year for any reason over 5 years). Thus, our study confirms the role of infliximab as an effective and overall well tolerated treatment optoion in the management of patients with this chronic condition." The 103 AS patients from 6 European countries (Belgium, Finland, France, Germany, the Netherlands and the United Kingdom) recruited to the 96-week open-label EASIC (European Ankylosing Spondylitis Infliximab Cohort) trial had previously participated in the 2-year randomised controlled trial ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy). The EASIC population consisted of 82.5% men and 17.5% women, with a mean age of 43.5 years. There was no major difference between the EASIC and ASSERT study populations in terms of demographics or age. Between the two trials, patients had a break from their clinical trial-prescribed treatment regime of 1.3÷±0.9 years, during which they were treated according to local clinical practice. According to differences in such local standards, one group of patients continued to receive IFX (group 2, n=89, 83 of whom went forward for analysis) and one group did not (group 1, n=14 all analysed). Of the latter, group 1a had relapsed (BASDAI >4 and physician global VAS >4) (n=9) and group 1b were in remission (n=5). Interestingly, all these relapsed patients (group 1a), who had not been treated with IFX during the period between the trials, flared at the time of start of EASIC. During EASIC, all patients (except for those who had remained in remission) were continuously treated with IFX 5mg/kg (mean dosage) at intervals of 6-8 weeks (at the discretion of the investigator, according to local clinical practice). The patients in group 2 (who had also continuously received IFX between the trials) and completed the trial (n=76) showed significant improvement at week 96 compared to the ASSERT trial baseline data in a number of assessments: * BASDAI (Bath AS Disease Activity Index): 6.4 at ASSERT baseline vs 2.5 at week 96 of EASIC (pNotes: Abstract number: SAT0258 About EULAR * The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations. * In line with The European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems. * The aims of EULAR are to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with rheumatic diseases. * In 2009, The EULAR Executive Committee launched the EULAR Orphan Disease Programme (ODP) which aims to provide funding to research programmes focused on furthering understanding of the disease mechanisms behind systemic sclerosis. Please see www.eular.org for further information. * Diseases of the bone and joints such as rheumatoid arthritis and osteoarthritis cause disability in 4-5% of the adult population and are predicted to rise as people live longer. * As new treatments emerge and cellular mechanisms are discovered, EULAR 2009 is set to be the biggest rheumatology event in Europe with over 13,500 scientists, physicians, allied health professionals, and related audiences in attendance from over 100 countries. Over the course of the congress, more than 300 oral and 1,700 poster abstract presentations will be featured, with 780 invited speaker lectures taking place in more than 150 sessions. * To find out more about the activities of EULAR, visit: http://www.eular.org Rory Berrie European League Against Rheumatism


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009